

**Preferred Drug List Committee
Meeting Agenda, Open Session
December 13, 2017 11:30am to 1pm**

Meeting Location

DXC Technology (formerly HP Enterprise Services) Capital Room
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

Board Members

Taylor Gill, PharmD., BCPS
Wayne Wallace, M.D.
Raymond Magee, M.D.
Megan Hedden, PharmD.

Robert Haneke, PharmD
Emily Prohaska, PharmD., BCACP
Donna Sweet, M.D.

KDHE-DHCF Staff

Carol Arace, Administrative Assistant

Annette Grant, RPh.

DXC / HID Staff

Karen Kluczykowski, RPh.
Nancy Perry, RN
Ellen McCaffrey, RN

Taylor DeRuiter, PharmD.

I. Call to Order

A. Announcements

II. Old Business

- A. Review and Approval of September 13, 2017 Meeting Minutes
- B. Consent Agenda Items
 - i. PDL New Drug Placements
 - 1. Coly-Mycin-S®

III. New Business

- A. Opioids-Short Acting - New Class: (Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, Hydromorphone, Levorphanol Tartrate, Meperidine, Morphine, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol)
*Includes all salt forms, single and combination ingredient products, and all brand and generic formulations.
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

- B. Glucocorticoids- Intermediate Potency Topical- New Drug: (Cordran®, Elocon®, Nolix®, Synalar®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- C. Glucocorticoids- Mild Potency Topical - New Drug: (Derma-Smoothe/FS Body® & Derma-Smoothe/FS Scalp®, Fluocinolone Body & Scalp, Capex®, Synalar®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- D. Immunomodulation Agents- Ankylosing Spondylitis- Class Review, New Agent: (Cimzia®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendation
- E. Immunomodulation Agents- Psoriatic Arthritis- Class Review, New Agent: (Cimzia®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendation
- F. Anticoagulants- New Agent: (Bevyxxa)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- G. Non-Steroidal Anti-inflammatory Drugs- Oral- New Agent: (Vivlodex®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- H. Anti-Infective/Steroid Combination- Ophthalmic- New Agent: (Zylet®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

IV. Open Public Comment

V. Adjourn

****THIS AGENDA IS SUBJECT TO CHANGE****